In liquid biopsy race, Freenome lands $65 million, led by Andreessen Horowitz

 Freenome, a two-year-old liquid biopsy diagnosis platform that detects the cell-free DNA sequencing of cancer, has raised a huge Series A round — $65 million — led by Andreessen Horowitz, which also led the company’s $5.5 million seed round less than a year ago.
Other investors in the deal include GV, Polaris Partners, Innovation Endeavors, Spectrum 28, Asset Management… Read More